An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo

scientific article

An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1017308518
P356DOI10.1186/1476-4598-9-28
P932PMC publication ID2828990
P698PubMed publication ID20128926
P5875ResearchGate publication ID41403902

P2093author name stringXin Wei
David E Green
Aws Abdul-Wahid
Jean Gariépy
Reza Kiarash
Melissa C Cheung
Leigh Revers
Subodini Perampalam
P2860cites workEvidence that glutamic acid 167 is an active-site residue of Shiga-like toxin IQ24651553
Crystal structure of the holotoxino from Shigella dysenteriae at 2.5 Å resolutionQ27729840
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.Q27824766
Cancer statistics, 2008Q27860585
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerQ27860681
The S100 protein family: history, function, and expressionQ28293937
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cellsQ28578219
New colorimetric cytotoxicity assay for anticancer-drug screeningQ29615418
Ricin A-chain requires c-Jun N-terminal kinase to induce apoptosis in nontransformed epithelial cellsQ30433997
Probing the surface of eukaryotic cells using combinatorial toxin librariesQ30699689
Engineering novel binding proteins from nonimmunoglobulin domainsQ33224761
The hemolytic uremic syndromesQ33368547
Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.Q34049372
Ligand-targeted therapeutics in anticancer therapyQ34152775
Immunotoxins containing Pseudomonas exotoxin A: a short historyQ35109789
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemiaQ35116184
Shiga toxins and apoptosisQ35593092
Induction of apoptosis by tumor cell-targeted toxinsQ35636355
Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoformsQ35782472
Ribosome-inactivating proteinsQ35859613
Management of cutaneous melanomaQ35877006
Ribosome inactivating proteins and apoptosisQ36055888
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanomaQ36781607
Development trends for monoclonal antibody cancer therapeutics.Q36790534
Development trends for new cancer therapeutics and vaccines.Q37055390
Melanoma biomarkers: current status and vision for the future.Q37357928
Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodesQ38426349
Escherichia coli shiga-like toxins induce apoptosis and cleavage of poly(ADP-ribose) polymerase via in vitro activation of caspasesQ39655730
Role of caspases in immunotoxin-induced apoptosis of cancer cellsQ40991218
Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44Q41652786
Mutations affecting the activity of the Shiga-like toxin I A-chainQ44645523
Production and Characterization of Monoclonal Antibody to a Melanoma Specific GlycoproteinQ45164578
Whatever happened to immunotoxins? Research, and hope, are still aliveQ47639092
A soluble protein characteristic of the nervous systemQ47721048
Timeline: Chemotherapy and the war on cancer.Q53313789
Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.Q54047541
Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells.Q54083194
The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain.Q54648744
Immunotoxin therapy of cancerQ56454451
Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant MelanomaQ63247804
Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cellsQ73248328
High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survivalQ73685094
A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancerQ73788268
CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic diseaseQ74099040
bcl-2 antisense therapy chemosensitizes human melanoma in SCID miceQ74165698
Shiga toxinsQ74609189
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patientsQ79401099
P304page(s)28
P577publication date2010-02-03
P1433published inMolecular CancerQ15724585
P1476titleAn evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo
P478volume9

Reverse relations

cites work (P2860)
Q36222432Alterations in the ribosomal machinery in cancer and hematologic disorders.
Q39367729Attempts to express the A1-GMCSF immunotoxin in the baculovirus expression vector system.
Q33934041Design of targeted B cell killing agents
Q34986254Immunotoxins: a promising treatment modality for metastatic melanoma?
Q33921062Interaction of ricin and Shiga toxins with ribosomes
Q38019016Ribosome-inactivating proteins with an emphasis on bacterial RIPs and their potential medical applications.
Q90629458Translation regulation in skin cancer from a tRNA point of view
Q37954333Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy.

Search more.